Overview
News Releases
Events & Presentations
Financials
Governance
Stock Information
Annual Report & Proxy
Resources

News Releases

News Releases

Mar 01, 2022
UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
-- UGN-301 is an investigational immunotherapy designed for monotherapy and combination therapy in treating low-grade and high-grade disease -- PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 1, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing
Read More
Feb 03, 2022
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
-- ENVISION Study Design Similar to Successful UGN-102 Phase 2b OPTIMA II Trial -- PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 3, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers,
Read More
Jan 05, 2022
UroGen Pharma to Present at Upcoming Conferences
PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 5, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare
Read More